



## Replimune to Present at Two Upcoming Investor Conferences

February 7, 2019

WOBURN, Mass., Feb. 07, 2019 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immunotherapies derived from its Immulytic™ platform, today announced that Robert Coffin, Ph.D., Chief Executive Officer and Director of Replimune, will participate in fireside chats and host investor meetings at the following two conferences.

Guggenheim Healthcare Talks Forum – Oncology Day

Date: Thursday, February 14, 2019

Presentation Time: 1:30 pm ET

Location: St. Regis in New York, NY

8<sup>th</sup> Annual SVB Leerink Global Healthcare Conference

Date: Thursday, February 28, 2019

Presentation Time: 2:00 pm ET

Location: Lotte New York Palace in New York, NY

### About Replimune

Replimune Group Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of “oncolytic immunotherapies” for the treatment of cancer. Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing effects of selective virus replication and the potency of the immune response to the tumor antigens released. The Company’s Immulytic™ platform is designed to maximize systemic immune activation, in particular to tumor neoantigens, through robust viral mediated immunogenic tumor cell killing and the delivery of optimal combinations of immune-activating proteins to the tumor and draining lymph nodes. The approach is expected to be highly synergistic with immune checkpoint blockade and other approaches to cancer treatment. Replimune intends to progress these therapies rapidly through clinical development in combination with other immuno-oncology products with complementary mechanisms of action. For more information, please visit [www.replimune.com](http://www.replimune.com).

### Replimune Contact

Pamela Esposito, Ph.D.

Replimune Group Inc.

617.233.6988

[pamela@replimune.com](mailto:pamela@replimune.com)

### Investor Inquiries

Chris Brinzey

Westwicke Partners, an ICR Company

339.970.2843

[chris.brinzey@westwicke.com](mailto:chris.brinzey@westwicke.com)

### Media Inquiries

Arleen Goldenberg

Verge Scientific Communications

917.548.1582

[agoldenberg@vergescientific.com](mailto:agoldenberg@vergescientific.com)

Source: Replimune Group Inc